Nucor earnings beat by $0.08, revenue fell short of estimates
WESTON, Mass. - ModeX Therapeutics Inc., a subsidiary of OPKO Health (NASDAQ:OPK), has established a Scientific Advisory Board to guide the development of its immunology and oncology portfolio, which includes multispecific antibodies and vaccines. With OPKO currently valued at a market capitalization of $1.08 billion and generating annual revenues of $689 million, this initiative was announced today, as the company aims to leverage the expertise of leading researchers in the field to advance its proprietary MSTAR platform technology.
The newly formed board features prominent scientists with significant contributions to biomedical research, including Drs. John Heymach, Ronald Levy, Myron Cohen, and Rafi Ahmed. Their collective experience spans cancer, immune-mediated diseases, and infectious diseases, aligning with ModeX’s focus on complex diseases involving the immune system.
ModeX’s President and CEO, Gary Nabel, expressed enthusiasm about the collaboration, highlighting the potential of the company’s next-generation immune therapies designed to target multiple disease pathways simultaneously. According to InvestingPro data, while OPKO maintains a healthy liquidity position with a current ratio of 2.49, the company’s EBITDA stands at -$173.41 million, reflecting substantial investments in research and development. The advisory board’s role will be to provide strategic insights into the clinical development of these innovative treatments.
The MSTAR platform technology underpins ModeX’s approach to creating multispecific antibodies, which are designed to bind four or more targets. This approach aims to address the complexity of diseases by harnessing the immune system more effectively than single-targeted medicines.
Currently, ModeX’s pipeline includes first-in-class drug candidates, with two assets in clinical trials and several more preparing to enter clinical stages. The company’s strategy underscores a commitment to advancing treatments for immune diseases, including various cancers and viral threats. For investors seeking deeper insights into OPKO’s financial health and growth prospects, InvestingPro offers comprehensive analysis with 7 additional ProTips and detailed metrics in its Pro Research Report, available as part of the subscription covering 1,400+ US stocks.
The creation of the advisory board is a step towards realizing the full potential of ModeX’s multispecific antibody technologies. ModeX Therapeutics, as part of OPKO Health, is based in Weston, Massachusetts, and focuses on developing unique therapeutics for complex diseases. The information about the formation of the Scientific Advisory Board and ModeX’s pipeline is based on a press release statement.
In other recent news, Opko Health reported its financial results for the first quarter of 2025, revealing a net loss that fell short of analyst expectations. The company posted an earnings per share (EPS) of -$0.10, missing the forecasted -$0.09, while revenue was $149.9 million, below the anticipated $163.14 million. Despite these challenges, the company noted a narrowed net loss compared to the same period last year, with strategic asset sales and cost reductions underway to enhance profitability. In a separate development, Opko Health’s Compensation Committee approved stock options and bonuses for its top executives, including CEO Dr. Phillip Frost, who received 500,000 stock options and a $480,000 bonus. Vice Chairman Dr. Jane H. Hsiao and President Dr. Elias A. Zerhouni also received substantial stock options and bonuses. The company is continuing its strategic focus on niche markets, with ongoing efforts in developing treatments for liver diseases affected by fatty liver disease. Additionally, Opko Health announced the sale of its oncology testing business to LabCorp, a move expected to yield significant cost savings and improve future profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.